Bavarian Nordic

Prospectus • Jan 27, 2010

Prospectus supplement no. 1 to prospectus of 8 January 2010 issued by Bavarian Nordic A/S

Prospectus supplement no. 1 to prospectus of 8 January 2010 issued by Bavarian Nordic A/S

Kvistgård, Denmark, January 27, 2010 - Bavarian Nordic A/S (OMX: BAVA) publishes today a prospectus supplement (the "Prospectus Supplement") which contains information regarding Bavarian Nordic A/S's pending suit against Oxford BioMedica as described in prospectus of 8 January 2010 (the "Prospectus") and should be read and construed in conjunction with the Prospectus. The Prospectus Supplement is considered to be incorporated in and to make up a component of the Prospectus. Prospectus supplement Following publication the Prospectus Supplement will be available for inspection at Bavarian Nordic A/S' office, Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark. The Prospectus Supplement is furthermore available on the website - except to persons subject to legislation prohibiting this - at www.bavarian-nordic.com, and will be available from: Nordea Bank Danmark A/S SEB Enskilda, Copenhagen Branch Securities Operations/HH7324 Silkegade 8 P. O. Box 850 DK-1113 Copenhagen K DK-0900 København C Tlf.: +45 36 97 74 00 Tlf.: +45 33 33 50 92 E-mail: prospekt@enskilda.dk E-mail: prospekt.ca@nordea.com Contact Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 Not for release, publication or distribution, directly or indirectly in or into Australia, Canada, Japan or the United States This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to buy the securities of Bavarian Nordic A/S (the "Securities") in Australia, Canada, Japan or the United States or in any other jurisdiction. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of the Offering in the United States or in any jurisdiction outside Denmark and the United Kingdom, and does not intend to conduct a public offering of the Securities in the United States or in any jurisdiction outside Denmark and the United Kingdom. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. Forward-looking statements This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. About Bavarian Nordic Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are under preparation for Phase III: IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute. Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA. For more information please visit www.bavarian-nordic.com [HUG#1377505]

Attachments:

• 2010-09-uk

  ---

  This content was distributed through

  

  - connecting communication professionals with their target audience. Visit us here.